Company Overview of Genta Incorporated
Genta Incorporated, a biopharmaceutical company, engages in the identification, development, and commercialization of novel drugs for the treatment of cancer and related diseases. Its products include Tesetaxel, a novel taxane compound that has completed Phase 2 trials in patients with advanced gastric cancer, breast cancer, bladder cancer, prostate cancer, and melanoma. The company is also developing G4544a, an orally bioavailable gallium-containing compound, which has completed a single-dose Phase 1 clinical study for the treatment of diseases associated with accelerated bone loss. In addition, it markets Ganite, an intravenous formulation of gallium nitrate to treat cancer-related hyperca...
200 Connell Drive
Berkeley Heights, NJ 07922
Founded in 1988
Key Executives for Genta Incorporated
Genta Incorporated does not have any Key Executives recorded.
Genta Incorporated Key Developments
SEC Orders Hearings On Registration Suspension Or Revocation Against Genta Incorporated For Failure To Make Required Periodic Filings
Sep 4 14
Securities and Exchange Commission (SEC or the commission) instituted public administrative proceeding to determine whether to revoke or suspend for a period not exceeding twelve months the registration of each class of the securities of Genta Incorporated for failure to make required periodic filings with the Commission. In this Order, the Division of Enforcement (Division) alleges that the company was delinquent in its required periodic filings with the Commission. In this proceeding, instituted pursuant to Exchange Act Section 12(j), a hearing will be scheduled before an Administrative Law Judge. At the hearing, the judge will hear evidence from the Division and the company to determine whether the allegations of the Division contained in the Order, which the Division alleges constitute failures to comply with Exchange Act Section 13(a) and Rules 13a-1 and 13a-13 there under, are true. The judge in the proceeding will then determine whether the registrations pursuant to Exchange Act Section 12 of each class of the securities of the company should be revoked or suspended for a period not exceeding twelve months. The Commission ordered that the Administrative Law Judge in this proceeding issue an initial decision not later than 120 days from the date of service of the order instituting proceeding.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries